While the biotech markets are down to start 2022, there is an optimistic view among biotech investors, according to Camille Samuels, partner at Venrock, a venture capital firm. Samuels participated in a panel discussion at Biotech Showcase 2022 and spoke with ScienceBoard as part of Biotech Finance Month.  

Dennis Purcell, founder Aisling Capital and one of the founders of the J.P. Morgan Healthcare Conference, shared his expert opinions on the state of the biotech sector and investment outlook with ScienceBoard as part of Biotech Finance Month 2022.  

2021 was an especially active year for private equity（PE）firms. According to PitchBook, the number of deals surged over 51% last year to top 8,600. Among the beneficiaries of the 29% increase in deals were biotool firms, which supply laboratory instrumentation and aftermarket supplies for the analysis of genes, cells, and proteins（excluding in vitro diagnostics tools）.  

CuriRx has launched its Advanced Bioprocessing and Analytical Center to provide end-to-end support to the developers of biotherapeutics.  

While the biotech markets are down to start 2022, there is an optimistic view among biotech investors, according to Camille Samuels, partner at Venrock, a venture capital firm. Samuels participated in a panel discussion at Biotech Showcase 2022 and spoke with ScienceBoard as part of Biotech Finance Month.  

Dennis Purcell, founder Aisling Capital and one of the founders of the J.P. Morgan Healthcare Conference, shared his expert opinions on the state of the biotech sector and investment outlook with ScienceBoard as part of Biotech Finance Month 2022.  

TetraScience and Datagrok have joined the Tetra Partner Network to enable customers to utilize TetraScience's Tetra Data as a trusted source for data-driven advanced analytics.  

2021 was an especially active year for private equity（PE）firms. According to PitchBook, the number of deals surged over 51% last year to top 8,600. Among the beneficiaries of the 29% increase in deals were biotool firms, which supply laboratory instrumentation and aftermarket supplies for the analysis of genes, cells, and proteins（excluding in vitro diagnostics tools）.  

Charles River Laboratories has expanded its strategic partnership with SAMDI Tech. The expanded agreement will provide Charles River's clients seamless access to the label-free, high-throughput screening mass spectrometry platform in drug discovery.  

Septerna has launched with $100 million in series A financing. The financing will enable the company to advance its emerging pipeline of novel G protein-coupled receptor-targeted drug programs.  

Ractigen Therapeutics has received $30 million in a series A financing round. Ractigen will use the proceeds to advance several programs from the preclinical to clinical phase as well as to scale up its oligonucleotide manufacturing capabilities.  

Active Motif has purchased Amaryllis Nucleics, a startup focused on proprietary RNA sequencing methods.  

Broad Sky Partners stated a strategic investment from Capital Constellation as well as its acquisition of Thomas Scientific.  

Atara Biotherapeutics has entered into a long-term strategic agreement with Fujifilm under which Fujifilm will acquire Atara's T-cell operations and manufacturing facility in Thousand Oaks, CA, for $100 million upfront, retaining Atara's current staff at the site. The firms will also enter a long-term supply agreement, which could extend to 10 years.  

Adimab has expanded its proprietary technologies available for use in drug development. The expansion will aid in the development of antibody and multispecific therapeutic modalities, the firm said.